Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
出版年份 2019 全文链接
标题
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
作者
关键词
-
出版物
Cancers
Volume 11, Issue 2, Pages 236
出版商
MDPI AG
发表日期
2019-02-19
DOI
10.3390/cancers11020236
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92
- (2018) Eugenio Morelli et al. BLOOD
- MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
- (2018) Nicola Amodio et al. Journal of Hematology & Oncology
- Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
- (2018) Nicola Amodio et al. LEUKEMIA
- Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS
- (2018) Nasrin Rastgoo et al. LEUKEMIA
- Current applications of multiparameter flow cytometry in plasma cell disorders
- (2018) T Jelinek et al. Blood Cancer Journal
- miR-22 suppresses DNA ligase III addiction in multiple myeloma
- (2018) Daniele Caracciolo et al. LEUKEMIA
- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
- (2017) A Besse et al. LEUKEMIA
- CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
- (2017) Chang-Xin Shi et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
- (2017) Maria Angelica Stamato et al. Oncotarget
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Mir-221/222 are promising targets for innovative anticancer therapy
- (2016) Maria Teresa Di Martino et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
- (2016) Nicola Amodio et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- (2016) Nicola Amodio et al. MOLECULAR CANCER THERAPEUTICS
- miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
- (2016) M Fulciniti et al. Blood Cancer Journal
- MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
- (2016) Lavinia Raimondi et al. Biomed Research International
- Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma
- (2015) Patryk Krzeminski et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
- (2015) A. Gulla et al. CLINICAL CANCER RESEARCH
- Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients
- (2015) Enrica Calura et al. Oncotarget
- Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
- (2015) Maria Rita Pitari et al. Oncotarget
- Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
- (2015) Chonglei Bi et al. Oncotarget
- Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
- (2015) Peter Tsvetkov et al. eLife
- MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy
- (2015) Esteban Orellana et al. Cancers
- Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1
- (2015) Oncotarget
- In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
- (2015) Maria Teresa Di Martino et al. Oncotarget
- Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro
- (2014) Giulia Marvaso et al. CANCER BIOLOGY & THERAPY
- MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches
- (2014) Marco Rossi et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth
- (2014) Junfeng Wang et al. INTERNATIONAL JOURNAL OF CANCER
- A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells
- (2014) Marzia Leotta et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation
- (2014) P. Gasparini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mir-34: A New Weapon Against Cancer?
- (2014) Gabriella Misso et al. Molecular Therapy-Nucleic Acids
- From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
- (2013) Marco Rossi et al. CURRENT DRUG TARGETS
- Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma
- (2013) Nicola Amodio et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer
- (2013) Luciano Cascione et al. PLoS One
- MicroRNAs in the Pathobiology of Multiple Myeloma
- (2012) Marta Lionetti et al. CURRENT CANCER DRUG TARGETS
- Editorial: [Hot Topic: New Approaches in the Treatment of Multiple Myeloma: From Target-based Agents to the New Era of microRNAs (Dedicated to the Memory of Prof. Salvatore Venuta)]
- (2012) P. Tassone et al. CURRENT CANCER DRUG TARGETS
- Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
- (2012) P. Tagliaferri et al. CURRENT CANCER DRUG TARGETS
- microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis
- (2012) Bing-Ya Liu ONCOLOGY REPORTS
- miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E -miR-155 transgenic mouse model
- (2012) S. K. Sandhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
- (2012) I. A. Babar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
- (2012) N Amodio et al. Cell Death & Disease
- Pathogenesis of Myeloma
- (2011) Kenneth C. Anderson et al. Annual Review of Pathology-Mechanisms of Disease
- Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors
- (2011) P. Neri et al. BLOOD
- Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
- (2011) Kenneth C. Anderson CLINICAL CANCER RESEARCH
- MicroRNA-155 targets the SKI gene in human melanoma cell lines
- (2011) Lauretta Levati et al. Pigment Cell & Melanoma Research
- Emerging therapies for the treatment of relapsed or refractory multiple myeloma
- (2010) Meletios A. Dimopoulos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling
- (2010) N C Gutiérrez et al. LEUKEMIA
- Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
- (2009) T Rückrich et al. LEUKEMIA
- Causes and consequences of microRNA dysregulation in cancer
- (2009) Carlo M. Croce NATURE REVIEWS GENETICS
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now